BLUE logo

bluebird bio (BLUE) Company Overview

Profile

Full Name:

bluebird bio, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 19, 2013

Indexes:

Not included

Website:

http://www.bluebirdbio.com

Description:

bluebird bio, Inc is a biotechnology company engaged in research, development, and commercialization of gene therapies for severe genetic diseases and cancer. The company was founded in 1992. The corporate headquarters is located in Cambridge, Massachusetts. The European headquarters is in Zug, Switzerland. The developments of bluebird bio Inc. are based on gene therapy. The company's oncology programs focus on developing new methods of immunotherapy based on T-cell therapy, including chimeric antigen receptor T-cell therapy and T-cell receptor therapy. The company has created an integrated product platform with broad therapeutic potential for multiple indications.

Key Details

Price

$6.01

Market Cap

$58.44 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$29.50 M(+720.04% YoY)

Annual EPS

-$38.60(+34.13% YoY)

PE Ratio

-

Annual ROE

-128.87%

Annual Debt To Equity

0.00

Beta

2.47

Events Calendar

Earnings

Next earnings date:

Mar 26, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 26, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Dec 13, 2024

Analyst ratings

Recent major analysts updates

Dec 31, 24 Barclays
Overweight
Nov 15, 24 RBC Capital
Sector Perform
Nov 15, 24 Barclays
Overweight
Nov 15, 24 B of A Securities
Neutral
Sep 25, 24 Wells Fargo
Equal-Weight
Sep 16, 24 Cantor Fitzgerald
Neutral
Aug 15, 24 RBC Capital
Sector Perform
Aug 15, 24 JP Morgan
Neutral
Aug 15, 24 Barclays
Overweight
Aug 15, 24 Baird
Outperform

Screeners with BLUE included

Growing Shares Outstanding
US stocks
Stocks with high beta
Stocks below SMA 200
Stocks recommended to hold
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$6.01
BLUE price is $6.01

Price All-time High

$3018.78
BLUE price is currently -99.80% below its historical high of $3018.78

Price Analysts Target

$20.00
BLUE price is currently -69.94% lower than the consensus analysts' forecast

Price Most Recent Change

-3.05%
BLUE price was down -3.05% on Feb 11, 2025

Price YTD Change

-27.92%
BLUE price is down -27.92% since January 1st

Price 3-Year Change

-95.43%
BLUE price is down -95.43% over the past 3 years

Market cap

Market Cap

$58.44 M
BLUE market capitalization is $58.44 million

Market Cap 3-Year Change

-87.49%
BLUE market capitalization is down -87.49% over the past 3 years

Market Cap All-time High

$7.54 B
BLUE market capitalization is currently -99.23% below its historical high of $7.54 billion

Market Cap Sector Rank

37.44%
BLUE market capitalization is higher than 37.44% of companies in Healthcare sector

Technical

Beta

2.47
BLUE beta is 2.47

200-day SMA

$13.51
BLUE price is currently -55.50% below its 200-day simple moving average

14-day RSI

32.52
BLUE 14-day relative strength index is 32.52

30-day Relative Volume

0.83
BLUE 30-day relative volume is 0.83

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$29.50 M
BLUE annual revenue is $29.50 million

Annual Revenue Analysts Estimate

$71.91 M
BLUE annual revenue is currently -58.98% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+720.04%
BLUE annual revenue is up +720.04% year-on-year

Annual Revenue Sector Rank

41.2%
BLUE annual revenue is higher than 41.2% of companies in Healthcare sector

Profit

Annual Gross Profit

-$4.03 M
BLUE annual gross profit is -$4.03 million

Annual Gross Margin

-13.66%
BLUE annual gross profit margin is -13.66%

Annual Operating Profit

-$244.26 M
BLUE annual operating income is -$244.26 million

Annual Operating Margin

-828.09%
BLUE annual operating profit margin is -828.09%

Annual Net Income

-$211.91 M
BLUE annual net profit is -$211.91 million

Annual Net Margin

-718.42%
BLUE annual net profit margin is -718.42%

EPS

Annual EPS

-$38.60
BLUE annual earnings per share is -$38.60

Annual EPS Analysts Estimate

-$21.00
BLUE annual earnings per share is currently +83.83% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+34.13%
BLUE annual earnings per share is up +34.13% year-on-year

Annual EPS Sector Rank

6.62%
BLUE annual earnings per share is higher than 6.62% of companies in Healthcare sector

ROA & ROE

Annual ROA

-35.65%
BLUE annual return on assets is -35.65%

Annual ROE

-128.87%
BLUE annual return on equity is -128.87%

EBIT & EBITDA

Annual EBIT

-$195.69 M
BLUE annual earnings before interest & taxes is -$195.69 million

Annual EBITDA

-$167.16 M
BLUE annual EBITDA is -$167.16 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
BLUE price to earnings ratio value is unknown

PE Ratio Sector Rank

-
BLUE price to earnings ratio is unknown

PB Ratio

PB Ratio

-10.10
BLUE price to book ratio is -10.10

PB Ratio Sector Rank

2.62%
BLUE price to book ratio is higher than 2.62% of companies in Healthcare sector

PS Ratio

PS Ratio

1.10
BLUE price to sales ratio is 1.10

PS Ratio Sector Rank

25.45%
BLUE price to sales ratio is higher than 25.45% of companies in Healthcare sector

Enterprise value

Enterprise Value

$356.20 M
BLUE enterprise value is $356.20 million

Enterprise Value Sector Rank

63.31%
BLUE enterprise value is higher than 63.31% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.64
BLUE EV/EBITDA is -1.64

EV/EBITDA Sector Rank

39.83%
BLUE EV/EBITDA is higher than 39.83% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

1.41
BLUE annual current ratio is 1.41

Annual Quick Ratio

1.29
BLUE annual quick ratio is 1.29

Leverage

Annual Debt To Equity

0.00
BLUE annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-11.97
BLUE annual interest coverage ratio is -11.97

Risk & Stability

Piotroski F-Score

3
BLUE piotroski f-score is 3

Altman Z-Score

-10.39
BLUE altman z-score is -10.39

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$619.16 M
BLUE annual total assets is $619.16 million

Annual Non Current Assets

$337.48 M
BLUE annual long term assets is $337.48 million

Annual Current Assets

$281.69 M
BLUE annual total current assets is $281.69 million

Annual Cash & Cash Equivalents

$221.75 M
BLUE annual cash & cash equivalents is $221.75 million

Equity

Annual Book Value

$194.54 M
BLUE annual book value is $194.54 million

Annual Working Capital

$81.57 M
BLUE annual working capital is $81.57 million

Liabilities

Annual Total Liabilities

$424.62 M
BLUE annual total liabilities is $424.62 million

Annual Total Long Term Liabilities

$224.51 M
BLUE annual total long term liabilities is $224.51 million

Annual Current Liabilities

$200.11 M
BLUE annual total current liabilities is $200.11 million

Annual Accounts Payable

$18.50 M
BLUE annual accounts payable is $18.50 million

Debt

Annual Total Debt

$330.33 M
BLUE annual total debt is $330.33 million

Annual Total Debt 1-Year Change

-10.01%
BLUE annual total debt is down -10.01% year-on-year

Annual Long Term Debt

$224.42 M
BLUE annual long term debt is $224.42 million

Annual Short Term Debt

$105.91 M
BLUE annual short term debt is $105.91 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$273.76 M
BLUE annual total expenses is $273.76 million

Annual Operating Expenses

$240.23 M
BLUE annual total operating expenses is $240.23 million

Annual Cost Of Goods Sold

$33.53 M
BLUE annual cost of goods sold is $33.53 million

Annual SGA

$165.51 M
BLUE annual SGA is $165.51 million

Annual D&A

$28.52 M
BLUE annual depreciation & amortization is $28.52 million

Annual Interest Expense

$16.35 M
BLUE annual interest expense is $16.35 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$235.05 M
BLUE annual cash flow from operations is -$235.05 million

Annual CFO 1-Year Change

+25.67%
BLUE annual cash flow from operations is up +25.67% year-on-year

Annual CFI

$154.95 M
BLUE annual cash flow from investing activities is $154.95 million

Annual CFI 1-Year Change

-38.13%
BLUE annual cash flow from investing activities is down -38.13% year-on-year

Annual CFF

$196.25 M
BLUE annual cash flow from financing activities is $196.25 million

Annual CFF 1-Year Change

+1020.2%
BLUE annual cash flow from financing activities is up +1020.2% year-on-year

Free CashFlow

Annual FCF

-$244.10 M
BLUE annual free cash flow is -$244.10 million

Annual FCF 1-Year Change

+25.9%
BLUE annual free cash flow is up +25.9% year-on-year

CAPEX

Annual CAPEX

$9.06 M
BLUE annual capital expenditures is $9.06 million

Annual CAPEX 1-Year Change

-31.43%
BLUE annual capital expenditures is down -31.43% year-on-year

Institutional Ownership

Similar stocks

HBIO logo
Harvard Bioscience (HBIO)
CNTX logo
Context Therapeutics (CNTX)
CTSO logo
Cytosorbents (CTSO)
IPSC logo
Century Therapeutics (IPSC)
YI logo
111 (YI)
STTK logo
Shattuck Labs (STTK)
RMTI logo
Rockwell Medical (RMTI)
KRON logo
Kronos Bio (KRON)
ACHL logo
Achilles Therapeutics (ACHL)

FAQ

  • What is the ticker symbol for bluebird bio?
  • Does bluebird bio pay dividends?
  • What sector is bluebird bio in?
  • What industry is bluebird bio in?
  • What country is bluebird bio based in?
  • When did bluebird bio go public?
  • Is bluebird bio in the S&P 500?
  • Is bluebird bio in the NASDAQ 100?
  • Is bluebird bio in the Dow Jones?
  • When was bluebird bio's last earnings report?
  • When does bluebird bio report earnings?
  • Should I buy bluebird bio stock now?

What is the ticker symbol for bluebird bio?

The ticker symbol for bluebird bio is NASDAQ:BLUE

Does bluebird bio pay dividends?

No, bluebird bio does not pay dividends

What sector is bluebird bio in?

bluebird bio is in the Healthcare sector

What industry is bluebird bio in?

bluebird bio is in the Biotechnology industry

What country is bluebird bio based in?

bluebird bio is headquartered in United States

When did bluebird bio go public?

bluebird bio's initial public offering (IPO) was on June 19, 2013

Is bluebird bio in the S&P 500?

No, bluebird bio is not included in the S&P 500 index

Is bluebird bio in the NASDAQ 100?

No, bluebird bio is not included in the NASDAQ 100 index

Is bluebird bio in the Dow Jones?

No, bluebird bio is not included in the Dow Jones index

When was bluebird bio's last earnings report?

bluebird bio's most recent earnings report was on Nov 14, 2024

When does bluebird bio report earnings?

The next expected earnings date for bluebird bio is Mar 26, 2025

Should I buy bluebird bio stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions